Association between FLT3-ITD and additional chromosomal abnormalities in the prognosis of acute promyelocytic leukemia.

Abstract

OBJECTIVES:

Internal tandem duplications of the Fms-like tyrosine kinase 3 gene (FLT3-ITD) and additional chromosomal abnormalities (ACA) are prognostic factors in patients with acute promyelocytic leukemia (APL). This study aimed to determine the effect of the association between FLT3-ITD and ACA in the prognosis of APL.

METHODS:

This was a retrospective cohort study including 60 patients with APL treated with all-trans retinoic acid (ATRA) and chemotherapy. Five-year overall survival (OS) and progression-free survival (PFS) were analyzed in patient groups according to the presence of FLT3-ITD and ACA.

RESULTS:

FLT3-ITD was an independent adverse factor for 5-year PFS, and ACA was an independent adverse factor for 5-year OS. There were significant differences in OS and PFS among the groups: FLT3-ITD-negative without ACA, FLT3-ITD-positive without ACA, FLT3-ITD-negative with ACA, and FLT3-ITD-positive with ACA. The OS times were 52.917, 45.813, 25.375, and 23.417 months, and the PFS times were 48.833, 38.563, 23.250, and 17.333 months, respectively.

CONCLUSION:

FLT3-ITD and ACA are associated with the poorest OS and PFS outcomes in patients with APL treated with chemotherapy plus ATRA.

• Authors: Minh Phuong Vu, Cuc Nhung Nguyen, Hoang Vu, Tuyet Mai Nguyen, Tuan Tung Nguyen, Phuong Thao Pham
• Journal: The Journal of international medical research (J Int Med Res) Vol. 50 Issue 12 Pg. 3000605221138490 (Dec 2022) ISSN: 1473-2300 [Electronic] England
• PMID: 36539954 (Publication Type: Journal Article)

Chemical References

• Tretinoin
• fms-Like Tyrosine Kinase 3
• FLT3 protein, human

Topics

• Humans
• Leukemia, Promyelocytic, Acute (diagnosis, drug therapy, genetics)
• Retrospective Studies
• Mutation (genetics)
• Chromosome Aberrations
• Prognosis
• Tretinoin (therapeutic use)
• Leukemia, Myeloid, Acute (drug therapy)
• fms-Like Tyrosine Kinase 3 (genetics, therapeutic use)